Trimetrexate glucuronate(Cat No.:I037525)is an active metabolite of trimetrexate, a potent inhibitor of dihydrofolate reductase (DHFR), which plays a critical role in folate metabolism and DNA synthesis. This compound has shown efficacy in treating certain types of cancer, particularly in patients with reduced response to conventional methotrexate therapy. Trimetrexate glucuronate enhances the therapeutic effects of trimetrexate by improving its solubility and bioavailability. Ongoing research focuses on its pharmacokinetics, mechanisms of action, and potential applications in combination therapies to optimize treatment outcomes for various malignancies.
Catalog Number | I037525 |
CAS Number | 82952-64-5 |
Synonyms | Trimetrexate glucuronate; DRG0183; DRG 0183; DRG-0183; CI898; CI-898; CI 898 |
Molecular Formula | C25H33N5O10 |
Purity | 98% |
Solubility | To be determined |
Appearance | Solid powder |
Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
IUPAC Name | 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine;(2S,3S,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid |
InChI | InChI=1S/C19H23N5O3.C6H10O7/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3;7-1-2(8)3(9)4(10)5(11)6(12)13/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24);1-5,8-11H,(H,12,13)/t;2-,3+,4-,5-/m.0/s1 |
InChIKey | ZCJXQWYMBJYJNB-LRDBBFHQSA-N |
SMILES | CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC.C(=O)[C@@H]([C@H]([C@@H]([C@@H](C(=O)O)O)O)O)O |
Reference | 1: Blanke CD, Chansky K, Christman KL, Hundahl SA, Issell BF, Van Veldhuizen PJ Jr, Budd GT, Abbruzzese JL, Macdonald JS. S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. Am J Clin Oncol. 2010 Apr;33(2):117-20. doi: 10.1097/COC.0b013e318199fb84. PubMed PMID: 19770625; PubMed Central PMCID: PMC2967385. |